The use of hydrolytic enzymes as adjuvant therapy in AIDS/ARC/LAS patients.
The purpose of this paper is to discuss a hypothesis corroborating the use of hydrolytic enzymes in AIDS/ARC/LAS patients, showing high levels of circulating immune complexes (CIC). Other diseases, revealing high CIC-levels as well, may be improved or even cured by eliminating CIC. The results obtained from experiences of CIC-elimination by hydrolytic enzymes are presented below. As may be determined from the data available, hydrolytic enzymes should be included in the therapy of HIV-positive patients. Clinical trials are being continued.
Stauder
G
G
Medizinische Enzymforschungsgesellschaft, Geretsried, FRG.
Ransberger
K
K
Streichhan
P
P
Van Schaik
W
W
Pollinger
W
W
D000386:AIDS-Related Complex / Q000188:drug therapy* / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000936:Antigen-Antibody Complex; D006801:Humans; D006867:Hydrolases / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010587:Phagocytosis; D010956:Plasmapheresis
D000936:Antigen-Antibody Complex; D007166:Immunosuppressive Agents; D006867:Hydrolases